Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model

Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model

Abstract In malignant glioma, cytotoxic drugs are often inhibited from accessing the tumor site due to the blood-tumor barrier (BTB). Ibrutinib, FDA-approved lymphoma agent, inhibits Bruton tyrosine kinase (BTK) and has previously been shown to independently impair aortic endothelial adhesion and in...

Full description

Saved in:
Bibliographic Details
Main Authors: Sanghee Lim, Minhye Kwak, Jeonghan Kang, Melissa Cesaire, Kayen Tang, Robert W. Robey, William J. E. Frye, Baktiar Karim, Donna Butcher, Martin J. Lizak, Mahalia Dalmage, Brandon Foster, Nicholas Nuechterlein, Charles Eberhart, Patrick J. Cimino, Michael M. Gottesman, Sadhana Jackson
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Acta Neuropathologica Communications
Subjects:
Glioma
Blood-tumor barrier
Endothelial cells
Ibrutinib
Doxil
Online Access:https://doi.org/10.1186/s40478-024-01763-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40478-024-01763-6

Similar Items